Supplementary Table 1. Characteristics of Patients Achieving a Partial Response to Dacomitinib (Phase I and Phase II) Duration Maximum % HER2 Interval from Duration of Study of PR to Change in Target EGFR Mutational Mutational Prior E/Ga to Prior E/G,a Response to Patient Phase D, Days Lesions on D Status Status Starting D, Days Days Prior E/Ga I b Unknown 42 1 481 Unknown 361 SD –54.3 I b Unknown 126 2 106 Unknown 332 PR –42.2 II Unknown 549 3 174 Unknown 279 PR –57.5 II Unknown 245 4 127 Unknown 224 PR –37.3 II Unknown 471 5 862+ Exon 21 485 PR –67.9 II Wild type 37 6 464+ G719X 1,133 PR –85.0 II Unknown 24 7 420+ Unknown 823 PR –46.7 II Unknown 189 8 421 Unknown 246 SD –100.0 II Unknown 244 9 71 Unknown 347 SD –54.8 a Most recent regimen of erlotinib/gefitinib in patients who received more than one prior regimen of erlotinib/gefitinib. b Received 45 mg. D, dacomitinib; E, erlotinib; G, gefitinib; PR, partial response; SD, stable disease; +, patient stayed as PR at the data cut-off.
Supplementary Table 1. Characteristics of Patients Achieving a Partial Response to Dacomitinib (Phase I and Phase II) Patient Study Phase Duration of PR to D, Days Maximum % Change in Target Lesions on D EGFR Mutational Status HER2 Mutational Status Interval from Prior E/Ga to Starting D, Days Duration of Prior E/G,a Days Response to Prior E/Ga 1 I b 481 –54.3 Unknown Unknown 42 361 SD 2 I b 106 –42.2 Unknown Unknown 126 332 PR 3 II 174 –57.5 Unknown Unknown 549 279 PR 4 II 127 –37.3 Unknown Unknown 245 224 PR 5 II 862+ –67.9 Exon 21 Unknown 471 485 PR 6 II 464+ –85.0 G719X Wild type 37 1,133 PR 7 II 420+ –46.7 Unknown Unknown 24 823 PR 8 II 421 –100.0 Unknown Unknown 189 246 SD 9 II 71 –54.8 Unknown Unknown 244 347 SD a Most recent regimen of erlotinib/gefitinib in patients who received more than one prior regimen of erlotinib/gefitinib. b Received 45 mg. D, dacomitinib; E, erlotinib; G, gefitinib; PR, partial response; SD, stable disease; +, patient stayed as PR at the data cut-off.